Wanbury Limited
Wanbury Limited, a listed mid-size Pharma company existing for several years in API. Wanbury has a basket of over 13 API products. It is the largest manufacturer of Metformin with over 8500 tons per year. Wanbury exports to over 50 countries, 65% of ...
Key Metrics
EPS
17.11
Current ratio
0.74
Debt/Equity
4.89
Debt/EBITDA
1.39
Interest coverage ratio
2.93
Operating Cashflow to total debt
0.03
Financials
Pros & Cons
Exclusive on TAP Bonds
Here's what we like about this company and potential risks we have identified.
Pros
Company has delivered good profit growth of 27.4% CAGR over last 5 years
Cons
Stock is trading at 20.0 times its book value
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 7.34% over past five years.
Promoters have pledged 76.7% of their holding.
Earnings include an other income of Rs.29.7 Cr.
Disclaimer: Tap Bonds gathers data directly from the respective OBPP websites but does not guarantee its accuracy. We do not offer investment advice or endorse the purchase of any securities mentioned, nor do we warrant the reliability of the information collected.
About Wanbury Limited bond.
This comprehensive profile covers key factual information about Wanbury Limited. Wanbury Limited, a listed mid-size Pharma company existing for several years in API. Wanbury has a basket of over 13 API products. It is the largest manufacturer of Metformin with over 8500 tons per year. Wanbury exports to over 50 countries, 65% of which comprises of regulated markets. It has two US-FDA approved multi-product API facilities. EPS in Mar-2024 was 17.11. Current ratio in Mar-2024 was 0.74. Debt/Equity in Mar-2024 was 4.89. Debt/EBITDA in Mar-2024 was 1.39. Interest coverage ratio in Mar-2024 was 2.93. Operating Cashflow to total debt in Mar-2024 was 0.03. Total revenue for Mar-2025(E) was ₹657.02. Net income for Mar-2025(E) stood at ₹57.08. Total assets as of Mar-2024 were ₹343.50. Operating cash flow for Mar-2024 was ₹3.98. Peers and comparison entities consist of Wanbury Limited, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr Reddy's Laboratories Limited. As of Dec 2024, promoters hold N/A% while others hold N/A% of equity. Key strengths include: Company has delivered good profit growth of 27.4% CAGR over last 5 years; ; ; ; . Key risks include: Stock is trading at 20.0 times its book value; Company has low interest coverage ratio.; The company has delivered a poor sales growth of 7.34% over past five years.; Promoters have pledged 76.7% of their holding.; Earnings include an other income of Rs.29.7 Cr.. Leadership team details include Anupama Vaidya (The chairman and an independent non-executive woman director), K Chandran (The vice chairman and whole time director), Mohan Kumar Rayana (whole-time director.), Pravin Dilip Pawar (Independent non-executive director), Jitendra J Gandhi (The company secretary and compliance officer), Mridul Sumanlal Mehta (Additional non-executive independent director), Vinod Verma (The chief financial officer), Pradeep Patni (The chief executive officer). This detailed corporate overview is structured to provide a thorough understanding of all available data points, enhance search visibility, and support investor analysis.